Dalts, I have always participated, last time I even got some of the shortfall.
The norm is a 10-15% increase per annum, mostly approved at the AGM. 100% is unheard off. If ALA can raise $ 10m for a pre-clinical iNKT that has been evaluated as not worth to be progressed by IMU, got an incompetent management that can't get the IND approved but is still valued $ 100m plus then anyone can do the same for CHM. What Hopper wants is again devaluing an almost ZERO valued company even more and at the same time destroying the data value of the science team. Why else did JC leave?
No to his insane plan, Yes to my plan.
GLTA
CHM Price at posting:
2.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)